TOMM20

Across TCGA pan-cancer cohorts, TOMM20 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TOMM20 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TOMM20 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TOMM20 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

CCRCC, HNSC, and UCEC are the cancer types where TOMM20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.377	0.867	<.001	24	view →
HNSC	DFS	Median	IV	0.891	0.658	.004	16	view →
UCEC	OS	Median	III,IV	0.884	0.492	.031	12	view →
LUAD	DFS	Quartile	II,III,IV	0.150	0.647	.001	8	view →
PDAC	DFS	Tertile	All	0.656	0.401	.017	7	view →
LSCC	DFS	Median	II,III,IV	1.000	0.836	.005	6	view →
GBM	OS	Tertile	All	0.990	0.742	.005	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TOMM20–CCRCC (DFS)

Open the CCRCC breakdown →